Evolent Health, Inc.

Evolent Health, Inc.

EVHยทNYSE

$3.78

-4.5%
HealthcareMedical - Healthcare Information Services

Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.

At a Glance

Live Snapshot
Market Cap$425.18M
EPS-5.0700
P/E Ratio-0.75
Earnings Date08/06/2026
evh

Evolent Health, Inc. Street Expectations Map

EVH ยท NYSE

Wall Street analysts project that EVH stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 6.38, with estimates ranging from a low of 3.50 to a high of 10.00.

Lowest Target
3.50
-7.41%
Consensus Target
6.38
68.78%
Highest Target
10.00
164.55%

The consensus 1-year price target stands at 6.38, with estimates ranging from a low of 3.50 to a high of 10.00.

Analyst Consensus Analysis

Upside Potential

+68.8%

Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.

Analyst Agreement

101.9% spread

High uncertainty. Very wide target spread indicates significant disagreement among analystsโ€”major valuation uncertainty or transformation underway.

Risk-Reward Profile

22.21x

Favorable risk-reward. Potential upside significantly exceeds downside risk, offering asymmetric return profile attractive for risk-tolerant investors.

Analyst Conviction

Low

High uncertainty: Wide dispersion indicates analysts struggle to agree on valuationโ€”proceed with caution and independent analysis.

Market Sentiment Insight

High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.

evh

Evolent Health, Inc. Forward Estimates of Revenue

EVH ยท NYSE
Latest Revenue
1.88B
FY 2025
Avg Estimate
2.41B
FY 2026
Estimate Range
2.25B - 2.55B
Analyst Spread

Forward Growth Analysis

Projected Growth+28.7%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage9 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread12%

Reasonable estimate spread indicates general agreement with normal forecast variance.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

evh

Evolent Health, Inc. Forward Estimates of Net Income

EVH ยท NYSE
Latest Net Income
-534.51M
FY 2025
Avg Estimate
36.96M
FY 2026
Estimate Range
30.65M - 43.27M
Analyst Spread

Forward Growth Analysis

Projected Growth+106.9%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage9 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread34%

Moderate uncertainty in forecastsโ€”typical for companies with evolving business models.

OutlookPositive

Generally favorable outlook with reasonable growth prospects and analyst support.

evh

Evolent Health, Inc. Forward Estimates of EPS

EVH ยท NYSE
Latest EPS
-5.07
FY 2025
Avg Estimate
$0.31
FY 2026
Estimate Range
$0.27 - $0.38
Analyst Spread

Forward Growth Analysis

Projected Growth+106.0%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage6 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread36%

Wide estimate range reveals significant forecast uncertainty and potential volatility.

OutlookPositive

Generally favorable outlook with reasonable growth prospects and analyst support.

evh

Evolent Health, Inc. Forward Estimates of EBIT

EVH ยท NYSE
Latest EBIT
-477.17M
FY 2025
Avg Estimate
-220.45M
FY 2026
Estimate Range
-232.44M - -205.69M
Analyst Spread

Forward Growth Analysis

Projected Growth+53.8%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage9 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread12%

Reasonable estimate spread indicates general agreement with normal forecast variance.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

evh

Evolent Health, Inc. Forward Estimates of EBITDA

EVH ยท NYSE
Latest EBITDA
-361.31M
FY 2025
Avg Estimate
-70.55M
FY 2026
Estimate Range
-74.39M - -65.83M
Analyst Spread

Forward Growth Analysis

Projected Growth+80.5%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage9 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread12%

Reasonable estimate spread indicates general agreement with normal forecast variance.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

evh

Evolent Health, Inc. Forward Estimates of SG&A Expense

EVH ยท NYSE
Latest SG&A Expense
303.87M
FY 2025
Avg Estimate
460.57M
FY 2026
Estimate Range
429.74M - 485.62M
Analyst Spread

Forward Growth Analysis

Projected Growth+51.6%

Strong growth expectations signal robust business momentum and market opportunity expansion.

Analyst Coverage9 Analysts

Moderate coverageโ€”sufficient for guidance but may lack depth of large-cap analysis.

Estimate Spread12%

Reasonable estimate spread indicates general agreement with normal forecast variance.

OutlookStrong

Positive analyst consensus with strong growth expectations and forecast confidence.

Key Insight

Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.

evh

Evolent Health, Inc. Insider Positioning

EVH ยท NYSE

During the last 12 months, insiders have purchased $38K and sold $26K worth of EVH shares, resulting in $13K of net buying activity.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

10.0K

38.20K

Sold

0

0.00

Net Activity

+38K

+$38K

9-12 Months

Bought

0

0.00

Sold

2.6K

25.62K

Net Activity

-26K

-$26K

Top Buyers

1
SBB

Springstubb Brendan B

Director

10.0K sharesโ€ข1 transactions

$38K

Top Sellers

1
SA

Shams Aammaad

Officer: Chief Accounting Officer

2.6K sharesโ€ข1 transactions

$26K

Insider Activity Analysis

Net Insider Sentiment

Bullish

Moderately bullish with $13K net buying. Insiders show cautious optimism through measured share purchases.

Buy/Sell Ratio

1.49:1

Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.

Insider Participation

Balanced

1 insider buyers and 1 sellers. Equal participation suggests mixed or neutral insider views.